Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline
Portfolio Pulse from
Candel Therapeutics is preparing to submit a Biologics License Application for its lead candidate, CAN-2409, targeting prostate cancer. The company is advancing its cancer treatment pipeline and aims for regulatory readiness by 2025.
March 13, 2025 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics is advancing its cancer treatment pipeline with a focus on regulatory readiness for CAN-2409, aiming for a BLA submission in prostate cancer.
The news of a BLA submission for CAN-2409 in prostate cancer is a significant milestone for Candel Therapeutics, indicating progress in their pipeline and potential future revenue. This development is likely to positively impact CADL's stock price in the short term as it reflects advancement towards regulatory approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100